Florbetapir
As of the edition of 20 October 2026, Florbetapir is a small molecule: marketed, first approved in 2012 (US); US protection ends in 2027.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2016
- Kind
- Small molecule
- Brand name
- Amyvid
- First approved
- 6 April 2012 (US)
- Approvals on record
- 8 in 3 regions
- Holder of the most recent approval
- Avid Radiopharmaceuticals; 5 holders in all
- Registered trials
- 58, 5 stopped early
- Disease areas
- Nervous system; Mental health; Nutrition and metabolism; Eye; Injuries; Inherited and neonatal
US protection
US protection ends in 2027.
The last listed US drug-substance patent ends in 2027. The application that gives this date is held by Avid Radiopharmaceuticals.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product8 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 8 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 10 | 9 | 0 | 1 |
| Phase 1 | 16 | 13 | 3 | 0 |
| Phase 2 | 16 | 9 | 2 | 2 |
| Phase 3 | 8 | 8 | 0 | 0 |
| Phase 4 | 8 | 5 | 1 | 2 |
| All trials | 58 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Avid Radiopharmaceuticals | Originator and Lead sponsor of trials | 2007 to now |
| Eli Lilly | Applicant and Lead sponsor of trials | 2013 to now |